体质指数在乳腺癌患者治疗中的应用  

Application of body mass index in treatment of breast cancer patients

作　　者：赵杰[1] ZHAO Jie(Department of l Breast Surgery of Sanmenxia Central Hospital Affiliated to Henan University of Science and Technology,Sanmenxia 472000 Henan,China)

机构地区：[1]河南科技大学附属三门峡市中心医院甲乳外科,河南三门峡472000

出　　处：《中国民康医学》2020年第11期107-108,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:探究体质指数(BMI)在乳腺癌患者治疗中的应用价值。方法:回顾性分析2013年3月至2018年2月108例术前行新辅助内分泌治疗乳腺癌患者的临床资料。根据BMI水平分为正常组(BMI<25 kg/m^2)74例和超重组(BMI≥25 kg/m^2)34例。比较两组近、远期疗效。结果:正常组治疗总有效率为81.08%,明显高于对照组的61.76%,差异有统计学意义(P<0.05);随访5年,两组病灶转移率、死亡率和生存率比较,差异均无统计学意义(P>0.05)。结论:BMI越低,乳腺癌患者术前行新辅助内分泌治疗的近期疗效越好,但BMI对其远期疗效影响不大。Objective:To investigate application value of body mass index(BMI)in treatment of breast cancer patients.Methods:The clinical data of 108 patients with preoperative neoadjuvant endocrine therapy for breast cancer from March 2013 to February 2018 were retrospectively analyzed.According to the BMI level,they were divided into normal group(74 cases,BMI<25 kg/m^2)and overweight group(34 cases.BMI≥25 kg/m^2).Then,the short-term and long-term efficacies of the two groups were compared.Results:The total effective rate in the normal group was 81.08%,which was significantly higher than 61.76%in the control group,and the difference was statistically significant(P<0.05).After 5 years of follow-up,there were no statistically significant differences in the rate of metastasis,mortality and survival rate between the two groups,and the differences were statistically significant(P<0.05).Conclusions:The lower the BMI is,the better the short-term efficacy of preoperative neoadjuvant endocrine therapy for breast cancer patients is However,BMI has little effect on its long-term efficacy.

关 键 词：体质指数 乳腺癌 新辅助内分泌治疗 近期疗效 5年生存率 

分 类 号：R737.9[医药卫生—肿瘤]